Analysed KALA BIO INC (KALA:NASDAQ) News Sources
Red Light Holland Engages Kala Bio’s Researgency.AI Platform to Support Clinical Development of Filament’s Patented PEX010 Botanical Psilocybin Drug Candidate
18-03-2026
yahoo.com
Aterian, Inc. Announces Definitive Agreement for the Sale of its Marquee Brand Portfolio for $18 Million Subject to Adjustments
28-04-2026
yahoo.com
Kala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and Precision Development Opportunities
01-04-2026
yahoo.com
KALA BIO Delivers Industry-Leading AI Infrastructure: Bionic Intelligence Research Agent Now Live
30-03-2026
yahoo.com
Kala Bio Celebrates Trump Executive Order as Game-Changer for Psychedelic Medicine
21-04-2026
yahoo.com
Kala Bio and Virotek Announce Letter of Intent to Establish an Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program
01-09-2026
yahoo.com
Kala Bio Targets Near-Term Revenue With Virotek Ophthalmology Genetic Testing Partnership
01-09-2026
advfn.com
Kala Bio and Virotek Finalize Definitive Agreement Establishing Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program
03-09-2026
yahoo.com
What is the current price of KALA BIO INC (KALA:NASDAQ)?
The current price of KALA BIO INC (KALA:NASDAQ) is $0.5724.
KALA BIO INC (KALA:NASDAQ) absolute price change since previous trading day?
The absolute price change of KALA BIO INC (KALA:NASDAQ) since the previous trading day is $0.0095.
KALA BIO INC (KALA:NASDAQ) percentage price change since previous trading day?
The percentage price change of KALA BIO INC (KALA:NASDAQ) since the previous trading day is 1.6877%.
What is the most recent average sentiment score for KALA BIO INC (KALA:NASDAQ)?
The most recent average sentiment score for KALA BIO INC (KALA:NASDAQ) is 74 out of 100.
What is the most recent average sentiment for KALA BIO INC (KALA:NASDAQ)?
The most recent sentiment for KALA BIO INC (KALA:NASDAQ) is .
SEC-8K** Filing Available For KALA BIO INC (KALA:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.